SENSIPAR Drug Patent Profile
✉ Email this page to a colleague
When do Sensipar patents expire, and what generic alternatives are available?
Sensipar is a drug marketed by Amgen and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.
This drug has eighty-one patent family members in twenty-nine countries.
The generic ingredient in SENSIPAR is cinacalcet hydrochloride. There are twenty-four drug master file entries for this compound. Twenty suppliers are listed for this compound. Additional details are available on the cinacalcet hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Sensipar
A generic version of SENSIPAR was approved as cinacalcet hydrochloride by AUROBINDO PHARMA LTD on March 8th, 2018.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for SENSIPAR?
- What are the global sales for SENSIPAR?
- What is Average Wholesale Price for SENSIPAR?
Summary for SENSIPAR
| International Patents: | 81 |
| US Patents: | 2 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 101 |
| Clinical Trials: | 17 |
| Patent Applications: | 153 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for SENSIPAR |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for SENSIPAR |
| What excipients (inactive ingredients) are in SENSIPAR? | SENSIPAR excipients list |
| DailyMed Link: | SENSIPAR at DailyMed |
Recent Clinical Trials for SENSIPAR
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| University of California, San Francisco | Phase 4 |
| VA Office of Research and Development | Phase 4 |
| Peter Vestergaard | Phase 3 |
Pharmacology for SENSIPAR
| Drug Class | Calcium-sensing Receptor Agonist |
| Mechanism of Action | Increased Calcium-sensing Receptor Sensitivity |
Paragraph IV (Patent) Challenges for SENSIPAR
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| SENSIPAR | Tablets | cinacalcet hydrochloride | 30 mg, 60 mg and 90 mg | 021688 | 1 | 2008-03-10 |
US Patents and Regulatory Information for SENSIPAR
SENSIPAR is protected by two US patents.
Patents protecting SENSIPAR
Rapid dissolution formulation of a calcium receptor-active compound
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING HYPERPARATHYROIDISM; METHOD OF TREATING HYPERCALCEMIA
Rapid dissolution formulation of a calcium receptor-active compound
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Amgen | SENSIPAR | cinacalcet hydrochloride | TABLET;ORAL | 021688-001 | Mar 8, 2004 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||
| Amgen | SENSIPAR | cinacalcet hydrochloride | TABLET;ORAL | 021688-002 | Mar 8, 2004 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||
| Amgen | SENSIPAR | cinacalcet hydrochloride | TABLET;ORAL | 021688-001 | Mar 8, 2004 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||
| Amgen | SENSIPAR | cinacalcet hydrochloride | TABLET;ORAL | 021688-002 | Mar 8, 2004 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for SENSIPAR
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Amgen | SENSIPAR | cinacalcet hydrochloride | TABLET;ORAL | 021688-002 | Mar 8, 2004 | ⤷ Sign Up | ⤷ Sign Up |
| Amgen | SENSIPAR | cinacalcet hydrochloride | TABLET;ORAL | 021688-003 | Mar 8, 2004 | ⤷ Sign Up | ⤷ Sign Up |
| Amgen | SENSIPAR | cinacalcet hydrochloride | TABLET;ORAL | 021688-001 | Mar 8, 2004 | ⤷ Sign Up | ⤷ Sign Up |
| Amgen | SENSIPAR | cinacalcet hydrochloride | TABLET;ORAL | 021688-003 | Mar 8, 2004 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for SENSIPAR
See the table below for patents covering SENSIPAR around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Poland | 3395339 | ⤷ Sign Up | |
| European Patent Office | 0724561 | ARYLALKYLAMINES AGISSANT SUR LES RECEPTEURS DU CALCIUM (CALCIUM RECEPTOR-ACTIVE ARYLALKYL AMINES) | ⤷ Sign Up |
| World Intellectual Property Organization (WIPO) | 9612697 | ⤷ Sign Up | |
| Japan | 2007145867 | CALCIUM RECEPTOR-ACTIVE ARYL ALKYLAMINE | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for SENSIPAR
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1203761 | SPC020/2005 | Ireland | ⤷ Sign Up | SPC020/2005: 20060407, EXPIRES: 20191021 |
| 1203761 | C01203761/01 | Switzerland | ⤷ Sign Up | PRODUCT NAME: CINACALCETUM; REGISTRATION NUMBER/DATE: SWISSMEDIC 56965 27.10.2004 |
| 1203761 | 91182 | Luxembourg | ⤷ Sign Up | 91182, EXPIRES: 20191022 |
| 1203761 | 300199 | Netherlands | ⤷ Sign Up | |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
